OUR SELECTION OF #IPNEWS AND ARTICLES OF THE WEEK

1. The Fate of the ‘Fearless Girl’ Statue Is in Question After the Permit for Its Place at the New York Stock Exchange Expired 

https://news.artnet.com/art-world/fearless-girl-statue-permit-expired-2043707

2. L’Officiel USA Hit With Lawsuit by New York City for Allegedly Failing to Pay Freelancers 

https://www.thefashionlaw.com/l-officiel-usa-hit-with-lawsuit-by-new-york-city-for-allegedly-failing-to-pay-freelancers/

3. The Gucci Family Hints at Litigation Again as House of Gucci Hits Theaters 

https://www.thefashionlaw.com/the-gucci-family-hints-as-litigation-again-as-house-of-gucci-hits-theaters/

4. Startup Seeks $20 Million to Let Facebook Use ‘Meta’ Trademark 

https://www.mandourlaw.com/blog/facebook-meta-trademark-dispute/

5. La strategia di Moderna alla base della decisione di non azionare i brevetti sui vaccini anti COVID-19 

https://www.corradini.it/la-strategia-di-moderna-alla-base-della-decisione-di-non-azionare-i-brevetti-sui-vaccini-anti-covid-19/

6. From Off-White Stripes to Red Zip Ties: Virgil Abloh’s Approach to Branding 

https://www.thefashionlaw.com/from-off-white-stripes-to-red-zip-ties-virgil-ablohs-approach-to-branding/

7. China’s National Intellectual Property Administration Releases English Language Guidelines on Trademark Protection and Enforcement 

https://www.chinaiplawupdate.com/2021/12/chinas-national-intellectual-property-administration-releases-english-language-guidelines-on-trademark-protection-and-enforcement/

8. The PTAB Desperately Needs Reform, Not Preservation 

https://www.ipwatchdog.com/2021/12/05/ptab-desperately-needs-reform-not-preservation/id=140805/

9. Level of attention – for advertising services 

https://legal-patent.com/trademark-law/level-of-attention-for-advertising-services/

10. U.S. President Biden Calls for Intellectual Property Protection Waivers After Omicron Discovery 

https://www.usnews.com/news/top-news/articles/2021-11-26/u-s-president-biden-calls-for-intellectual-property-protection-waivers-on-covid-19-vaccines